Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics (Premium)
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Deltex Medical Group PLC Announces FDA approval For CardioQ-ODM+


Wednesday, 23 Oct 2013 02:00am EDT 

Deltex Medical Group PLC announced that it has received approval from the US Food and Drug Administration (FDA) to market the CardioQ-ODM+ monitor in the USA. The CardioQ-ODM+ is the first haemodynamic monitoring system to combine cardiac output measurements derived from aortic flow (ODM) and arterial pressure (Pulse Pressure Waveform Analysis 'PPWA'). Pre-launch marketing at the recent annual congress of the American Society of Anesthesiologists has generated considerable interest and included the inaugural meeting of an expert group of clinicians combining academics and early implementers of ODM. 

Related Company News

Company Quote

9.875
0.0 +0.00%
30 Jul 2014